Overexpression of Nucleolin and Associated Genes in Prostate Cancer - Université Paris Cité Access content directly
Journal Articles International Journal of Molecular Sciences Year : 2022

Overexpression of Nucleolin and Associated Genes in Prostate Cancer


Prostate cancer (PCa) is the second most frequent cancer and the fifth leading cause of cancer death in men worldwide. If local PCa presents a favorable prognosis, available treatments for advanced PCa display limiting benefits due to therapeutic resistances. Nucleolin (NCL) is a ubiquitous protein involved in numerous cell processes, such as ribosome biogenesis, cell cycles, or angiogenesis. NCL is overexpressed in several tumor types in which it has been proposed as a diagnostic and prognostic biomarker. In PCa, NCL has mainly been studied as a target for new therapeutic agents. Nevertheless, little data are available concerning its expression in patient tissues. Here, we investigated the expression of NCL using a new cohort from Mondor Hospital and data from published cohorts. Results were then compared with NCL expression using in vitro models. NCL was overexpressed in PCa tissues compared to the normal tissues, but no prognostic values were demonstrated. Nine genes were highly co-expressed with NCL in patient tissues and tumor prostate cell lines. Our data demonstrate that NCL is an interesting diagnostic biomarker and propose a signature of genes co-expressed with NCL.
Fichier principal
Vignette du fichier
Firlej_Soyeux_Nourieh et al..._Overexpression_2022.pdf (19.04 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03663714 , version 1 (10-05-2022)





Virginie Firlej, Pascale Soyeux, Maya Nourieh, Eric Huet, Fannie Semprez, et al.. Overexpression of Nucleolin and Associated Genes in Prostate Cancer. International Journal of Molecular Sciences, 2022, 23 (9), pp.4491. ⟨10.3390/ijms23094491⟩. ⟨hal-03663714⟩
115 View
59 Download



Gmail Facebook X LinkedIn More